Type 2 Diabetes

A study from EASD 2021 suggests increased insulin resistance could help predict risk of incident stroke events among adult patients with type 2 diabetes, with results indicating lowest levels of insulin resistance were at a 40% lower risk of stroke compared to those with the highest levels.

An analysis of NHANES data presented at EASD 2021 details the effects of returning to a healthy weight among patients with obesity compared to those currently with obesity and those who always maintained a healthy weight.

An analysis of patient data from a national registry in Denmark indicates use of alendronate was associated with reductions in odds of developing type 2 diabetes, with this reduction becoming greater with longer use of the osteoporosis medication.

In patients with T2D without prior CVD, chronic kidney disease was the single risk factor associated with highest risk of MACE.

A posthoc analysis of the REWIND trial is providing insight into the overall standard of care seen with women with diabetes and increased cardiovascular risk compared to their male counterparts with diabetes and increased cardiovascular risk.

September's endocrine month in review features news related to diabetes, polycystic ovary syndrome, warnings from the FDA and FTC, and a column from Dr. Paul Thompson.

Sotagliflozin reduced HbA1c by 0.42% and heart failure by 32% in comparison to placebo.

Episode 2 of HCPLive Crisis Point tackles the clinical aspects and potential burdens clinicians face in the pursuit of obesity care.

A meta-analysis builds upon previous research and provides new insight into the total costs of diagnosis and treating PCOS as well as the costs of treating PCOS-related comorbidities.

In his recent presentation, Dr. Sperling spoke of how a greater focus needed to be made on the implementation of cardiovascular care strategies, as well as better utilization of health system approaches.

The risk of TB was 48% higher in patients with diabetes compared to those without diabetes, while participants with IFG showed no increased risk of TB incidence.

The approval, which was announced in a statement on September 20, makes Byooviz (ranibizumab-nuna) the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions.

A total of 269 participants were considered potentially overtreated, while 109 participants were appropriately on target, and 56 participants potentially undertreated.

Jennifer Green, MD, explains how delays in the adoption of new guideline recommendations are holding back optimal management of type 2 diabetes in the US.

Erica P. Gunderson, PhD, MS, MPH, offers perspective on the current state of gestational diabetes management as well as avenues for improving current diagnostic and management standards.

HCPLive Crisis Point takes an in-depth look at the obesity crisis, beginning with the process of medical diagnosis and who is impacted the most by the disease.

Vivian Fonseca, MD, reflects on the 100-year anniversary of the discovery of insulin and how the role of insulin has evolved since Sir Frederick Banting's historic discovery.

After presenting at TMIOA's 5th Heart in Diabetes meeting, Silvio Inzucchi, MD, reviews current knowledge related to the effects of diabetes medications on stroke risk.

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

Silvio Inzucchi, MD, discusses his presentation on the role of diabetes medications, including SGLT2 inhibitors and GLP-1 RAs, in stroke prevention from TMIOA's 5th Heart in Diabetes conference.

A discussion on the winning qualities of the CARDIA study, and why it's also hard to replicate.

A 12-week trial assessing the effects of a low calorie, low carbohydrate diet facilitated by community pharmacists suggests this approach could contribute to the remission of type 2 diabetes in adult patients.

Dr. Javed Butler referenced several promising ongoing trials of diabetes-related medications and their effects on heart disease but added that unclear guidelines kept them from being properly acknowledged.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

The Tulane Chief of Endocrinology recalls Dr. Frederick Banting's historic discovery in 1921, and how it still impacts diabetes care today.

Women with gestational diabetes face a twice greater risk of developing cardiovascular disease. Investigators are still seeking understanding of the association.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.